Life sciences & healthcare legal cluster: Hub · Dawn raid · VBP · Hospital AR · Exclusive agency · HGR · Trial injury · CRO/CDMO · Device liability · Labeling · SaMD · Patent linkage · License · FDA WL · MDR/IVDR · Internet hospital · Trade secrets · Pharma ads · Device distribution · Sources · Checklist
Triage in the first 72 hours
- Confirm scope: which FEI/site, which products, which systems (quality unit, lab, clinical, PV).
- Stand up a response cell: quality, regulatory, legal (US + PRC), IT/forensics, communications.
- Litigation hold on relevant systems; stop “cleanup” that looks like destruction of evidence.
- Map whether the same facts touch NMPA vigilance, manufacturing licences, or clinical trial authorisations in China.
How Warning Letters usually read for China sites
Recurring themes include incomplete investigations, inadequate CAPA effectiveness checks, data integrity (shared passwords, audit-trail gaps, trial-and-error testing), supplier control, and clinical monitoring failures. Pair US counsel drafting with local factory/site reality—promises that ignore China labour, vendor, or HGR constraints create the next letter.
Response architecture
1. Point-by-point ownership
Every observation needs: root cause (not restating the observation), CAPA with owners and dates, effectiveness checks, and residual risk. Global template language without site-level evidence fails inspections.
2. Data integrity workstream
Audit trails, analyst training, paper–electronic reconciliation, and CRO oversight if clinical data is implicated. See also trial data fraud red line.
3. China legal overlays
Employee interviews, labour discipline, and vendor termination must follow PRC employment and contract rules. Do not assume US “at-will” cleanup. If samples or sequence data move for retesting offshore, check HGR and data export.
Dual-regulator risk
A US letter can prompt Chinese counterparties, hospitals, or investors to ask hard questions. Align securities disclosure (if listed), customer notifications, and tender eligibility narratives. Do not issue inconsistent root-cause stories to FDA vs NMPA vs customers.
Inspection readiness after the letter
- Mock inspection with bilingual SMEs.
- Document hierarchy: what is shown first; what requires counsel presence.
- Translator protocol—technical accuracy over “polite English.”
- Escalation path if investigators request personal devices or WeChat.
Related outbound pages
EU MDR/IVDR enforcement · License-in/out · Hub
FAQ · 高频检索问题
Chinese long-tail intents mapped to this guide (orientation only).
FDA Warning Letter 中国厂家如何应对？
Warning Letter 是否等于产品自动禁售？
临床数据问题是否也会出 Warning Letter？
Need sector counsel?
Map your issue to a specialty desk: Life sciences & healthcare · Devices & IVD · Clinical & health data · Product liability · Industry hub.
Find counsel